Hair Growth Supplement and Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Supplements, Pharmaceuticals, Devices) Region and Competition 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 7.65 Billion
CAGR (2026-2031)	6.43%
Fastest Growing Segment	Supplements
Largest Market	North America
Market Size (2031)	USD 11.12 Billion

Market Overview

The Global Hair Growth Supplement and Treatment Market will grow from USD 7.65 Billion in 2025 to USD 11.12 Billion by 2031 at a 6.43% CAGR. The Global Hair Growth Supplement and Treatment Market encompasses a diverse array of pharmaceutical formulations, dietary supplements, and therapeutic devices designed to stimulate hair follicles and improve scalp health. The primary drivers supporting the market's growth include a globally aging population increasingly susceptible to androgenetic alopecia and a heightened psychological emphasis on personal aesthetics, which compels individuals to seek restorative solutions at earlier stages of hair thinning. Furthermore, rising stress levels and shifts in dietary habits have broadened the consumer base, necessitating effective remediation beyond traditional demographics.

Recent data underscores this robust consumer commitment to aesthetic maintenance. According to the Council for Responsible Nutrition, in 2024, 26% of dietary supplement users in the United States utilized products specifically to support skin, hair, and nail health. Despite this sustained demand, the market encounters a significant challenge in the form of stringent regulatory requirements for novel pharmaceutical agents, which can prolong approval timelines and impede the commercialization of innovative clinical treatments.

Key Market Drivers

The expansion of direct-to-consumer e-commerce channels and the increasing adoption of personalized treatment regimens are fundamentally reshaping market accessibility. By leveraging telemedicine platforms, companies now offer prescription-grade hair loss solutions and customized nutraceutical formulations directly to users, reducing the stigma associated with seeking treatment. This model fosters high retention rates through subscription-based services that adapt to individual physiological needs, effectively broadening the consumer base beyond traditional demographics. According to Hims & Hers Health, Inc., November 2024, in the 'Third Quarter 2024 Financial Results', the company reported that its subscriber base grew to a record 2.0 million, driven significantly by the demand for personalized health solutions. This trajectory confirms a consumer shift toward digitized health management where convenience is paramount for sustaining long-term therapeutic adherence.

Concurrently, technological advancements in non-invasive restoration and novel pharmaceutical agents are propelling the market by addressing previously unmet medical needs. The industry is transitioning toward sophisticated biotechnology and immunomodulatory treatments, particularly for autoimmune conditions like alopecia areata. This innovation is supported by venture capital aimed at commercializing breakthrough mechanisms of action. According to Pelage Pharmaceuticals, February 2024, in the 'Pelage Pharmaceuticals Announces $16.75 Million Series A Financing' press release, the company secured capital to advance PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells. Such investments are validated by regulatory milestones; according to Sun Pharmaceutical Industries Ltd., in 2024, the U.S. FDA approved LEQSELVI for treating severe alopecia areata, significantly expanding the therapeutic landscape.

Download Free Sample Report

Key Market Challenges

Stringent regulatory requirements for novel pharmaceutical agents constitute a substantial impediment to the growth of the Global Hair Growth Supplement and Treatment Market. Regulatory agencies enforce rigorous testing protocols to verify safety and efficacy, which inevitably prolongs the development timeline for new clinical treatments. This lengthy approval process creates a disconnect between the pace of innovation and market accessibility, forcing companies to endure extended periods of capital expenditure without revenue generation. As a result, the commercialization of advanced formulations is delayed, limiting the industry's ability to introduce next-generation therapies that could drive higher market valuation.

This bottleneck is particularly restricting given the surging volume of individuals actively seeking restoration services. According to the International Society of Hair Restoration Surgery, in 2024, the average number of patients per member physician increased by 20% compared to 2021 levels. This rise in patient density demonstrates a robust appetite for effective treatments. However, because regulatory delays prevent the market from fully leveraging this demand with novel pharmaceutical options, the industry struggles to convert this heightened consumer interest into immediate revenue through advanced product offerings.

Key Market Trends

The market is witnessing a surge in plant-based, vegan, and clean label formulations as consumers increasingly prioritize safety and holistic wellness over synthetic pharmacotherapy. This shift is driving the reformulation of hair health products to exclude hormones and artificial additives, relying instead on standardized botanicals to target root causes like stress without adverse side effects. This transition toward drug-free efficacy is evidenced by the sustained performance of leading natural brands. According to Unilever, August 2025, in the 'What's behind Unilever's first half results?' report, its Wellbeing business group, led by the plant-based brand Nutrafol, delivered strong double-digit growth for the 21st consecutive quarter, highlighting the robust demand for scientifically backed, nature-derived solutions.

Concurrently, the proliferation of clinical-grade at-home hair growth devices is democratizing access to advanced restoration therapies previously restricted to professional clinics. Technological miniaturization has enabled the mass commercialization of sophisticated low-level laser therapy (LLLT) and LED wearables that offer users professional-level efficacy with the convenience of autonomous home use. This segment is expanding rapidly as consumers seek non-invasive, cost-effective alternatives to surgical procedures or long-term medication. According to The Industry.beauty, September 2025, in the 'Beauty Tech Group targets £320m valuation ahead of stock market debut' article, the Beauty Tech Group reported that sales rose 27% to £55.2 million in the first half of 2025, a surge driven by the intensifying global uptake of its at-home hair restoration devices.

Segmental Insights

The Supplements segment is anticipated to witness the fastest growth in the Global Hair Growth Supplement and Treatment Market, driven by a heightened consumer preference for oral preventive care. This expansion is supported by growing recognition of the correlation between nutritional deficiencies and hair health, fueling demand for formulations containing vitamins and minerals. Additionally, the classification of these products as dietary aids rather than pharmaceutical drugs by regulatory bodies such as the U.S. Food and Drug Administration facilitates easier market access and direct availability, thereby accelerating adoption rates among health consumers.

Regional Insights

North America holds the dominant position in the global hair growth supplement and treatment market, primarily driven by high consumer awareness regarding hair restoration and a significant prevalence of alopecia. The region benefits from a well-established healthcare and retail infrastructure that facilitates easy access to diverse product lines. Furthermore, the presence of major manufacturers within the United States supports continuous product availability. Consumer confidence is reinforced by the United States Food and Drug Administration (FDA), which provides essential regulatory oversight for clinical hair loss treatments, ensuring market stability and adherence to safety standards.

Recent Developments

• In July 2025, Vegamour expanded its portfolio in the hair growth market with the commercial launch of its GRO+ Advanced Hair Growth & Density Supplements. This new offering featured a dual-pill system, including a botanical DHT blocker and a nutrient-rich soft gel, formulated to address biological causes of hair thinning such as hormonal imbalances and oxidative stress. The product release followed a clinical trial which reported significant reductions in shedding and improvements in hair density among participants. This launch underscored the company’s focus on plant-based, biotechnology-driven solutions for hair longevity and utilized novel delivery systems to enhance ingredient absorption.
• In October 2024, Force Factor announced a strategic collaboration with Nutrition21 to launch a new product line titled Hair Growth Accelerator. This supplement range was formulated with Lustriva, a patented complex of bonded arginine silicate and magnesium biotinate developed by Nutrition21. The partnership focused on delivering a science-backed solution evidenced to support hair thickness and growth within weeks of use. The launch included clinical-strength capsules and soft chews designed to improve hair health and density, catering to the growing consumer demand for effective, non-prescription hair growth interventions and broadening the accessibility of specialized nutritional support.
• In July 2024, Sun Pharmaceutical Industries Limited received approval from the U.S. Food and Drug Administration for Leqselvi (deuruxolitinib), an oral medication for the treatment of severe alopecia areata in adults. The approval was based on data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 clinical trials, which demonstrated significant scalp hair regrowth in patients with severe hair loss. This regulatory milestone marked the introduction of a new Janus kinase (JAK) inhibitor specifically indicated for this autoimmune condition, expanding the available therapeutic options in the global hair loss treatment market and offering a new daily oral regimen for affected patients.
• In February 2024, Pelage Pharmaceuticals completed a $16.75 million Series A financing round led by GV to advance a novel regenerative medicine treatment for hair loss. The investment was designated to support the clinical development of PP405, a topical small molecule designed to reactivate dormant hair follicle stem cells and restart the hair growth cycle. This funding enabled the biotechnology company to progress its lead candidate into Phase 2a clinical trials for androgenetic alopecia. The company focused on targeting the metabolic processes that regulate stem cell activation, aiming to provide a first-in-class solution for patients experiencing various types of hair loss.

Key Market Players

• Nutraceutical Wellness Inc.
• Viviscal Limited.
• GNC Holdings, Inc.
• Procter & Gamble
• InVite Health
• Johnson & Johnson Services, Inc
• Merck & Co., Inc.
• Curallux, LLC.
• iRestore Hair Growth System
• Lexington International, LLC

By Type	By Region
Supplements Pharmaceuticals Devices	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Hair Growth Supplement and Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Hair Growth Supplement and Treatment Market, By Type:

• Supplements
• Pharmaceuticals
• Devices

• Hair Growth Supplement and Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE